| human | Q5 |
| P734 | family name | Redfield | Q16881969 |
| Redfield | Q16881969 | ||
| Redfield | Q16881969 | ||
| P735 | given name | Margaret | Q4963612 |
| Margaret | Q4963612 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q88787193 | A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction |
| Q35672064 | A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. |
| Q37505066 | A functional genetic variant (N521D) in natriuretic peptide receptor 3 is associated with diastolic dysfunction: the prevalence of asymptomatic ventricular dysfunction study |
| Q35283673 | A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. |
| Q37255814 | A modifier screen identifies DNAJB6 as a cardiomyopathy susceptibility gene |
| Q42024455 | A modifier screen identifies DNAJB6 as a cardiomyopathy susceptibility gene |
| Q34297026 | A randomized pilot study of aortic waveform guided therapy in chronic heart failure |
| Q41713263 | A survey of clinician attitudes and self-reported practices regarding end-of-life care in heart failure |
| Q37304801 | Abnormal cardiac structure and function in the metabolic syndrome: a population-based study |
| Q50078700 | Abundance, localization, and functional correlates of the advanced glycation end-product carboxymethyl lysine in human myocardium. |
| Q38375946 | Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices |
| Q43917399 | Actions of a novel synthetic natriuretic peptide on hemodynamics and ventricular function in the dog. |
| Q45110607 | Acute and chronic reduction of functional mitral regurgitation in experimental heart failure by percutaneous mitral annuloplasty |
| Q80589437 | Acute and chronic ventricular-arterial coupling in systole and diastole: insights from an elderly hypertensive model |
| Q37044895 | Acute decompensated heart failure and the cardiorenal syndrome |
| Q37408637 | Acute heart failure with preserved ejection fraction: unique patient characteristics and targets for therapy |
| Q37366116 | Advanced glycation end products accumulate in vascular smooth muscle and modify vascular but not ventricular properties in elderly hypertensive canines |
| Q96222358 | Advancing Research on the Complex Interrelations Between Atrial Fibrillation and Heart Failure: A Report From a US National Heart, Lung, and Blood Institute Virtual Workshop |
| Q90748039 | Adverse Renal Response to Decongestion in the Obese Phenotype of Heart Failure With Preserved Ejection Fraction |
| Q51838398 | Age- and gender-related ventricular-vascular stiffening: a community-based study. |
| Q37366030 | Age-associated increases in pulmonary artery systolic pressure in the general population |
| Q61663352 | Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population |
| Q36762703 | Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population |
| Q38885478 | Ambulatory Hemodynamic Monitoring Reduces Heart Failure Hospitalizations in "Real-World" Clinical Practice |
| Q37108057 | Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction |
| Q37109794 | Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure |
| Q36882168 | Anemia and heart failure: a community study |
| Q44391152 | Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure |
| Q39405472 | Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial |
| Q93053031 | Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction |
| Q42722674 | Anodal stimulation: an underrecognized cause of nonresponders to cardiac resynchronization therapy. |
| Q28535743 | Anti-remodeling effects of rapamycin in experimental heart failure: dose response and interaction with angiotensin receptor blockade |
| Q38381276 | Aortic Waveform Analysis to Individualize Treatment in Heart Failure. |
| Q33659958 | Aortic root remodeling over the adult life course: longitudinal data from the Framingham Heart Study |
| Q94547829 | Artificial Intelligence in Cardiology: Present and Future |
| Q57540318 | Association of newer diastolic function parameters with age in healthy subjects: a population-based study. |
| Q79753571 | Association of obesity with left ventricular remodeling and diastolic dysfunction in patients without coronary artery disease |
| Q45182590 | Atrial BNP endocrine function during chronic unloading of the normal canine heart |
| Q35569621 | Atrial fibrillation and mortality in heart failure: a community study |
| Q35805182 | Atrial fibrillation and ventricular dysfunction: a vicious electromechanical cycle |
| Q37638257 | Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up study |
| Q53442043 | B-type natriuretic peptide levels and continuous-flow left ventricular assist devices. |
| Q93551171 | B-type natriuretic peptide single nucleotide polymorphism rs198389 and survival in the general community |
| Q93551292 | B-type natriuretic peptide single nucleotide polymorphism rs198389 is highly prevalent and impacts test characteristics of common assays |
| Q48417679 | BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors |
| Q56967474 | Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial |
| Q34144039 | Beta-blockers: new standard therapy for heart failure |
| Q37256856 | Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide |
| Q46844264 | Bioenergetic protection of failing atrial and ventricular myocardium by vasopeptidase inhibitor omapatrilat |
| Q92130328 | Biomarker Profile of Left Atrial Myopathy in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial |
| Q39215627 | Biomarker-based risk prediction in the community |
| Q37419451 | Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction |
| Q35040738 | Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic |
| Q39787354 | Cardiac AAV9 Gene Delivery Strategies in Adult Canines: Assessment by Long-term Serial SPECT Imaging of Sodium Iodide Symporter Expression. |
| Q92465952 | Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP |
| Q35671472 | Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community |
| Q37380080 | Cardiac output response to exercise in relation to metabolic demand in heart failure with preserved ejection fraction |
| Q36026805 | Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota |
| Q42475794 | Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload |
| Q36415902 | Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network |
| Q34046332 | Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study |
| Q35629821 | Care in the last year of life for community patients with heart failure |
| Q35750487 | Central obesity: association with left ventricular dysfunction and mortality in the community |
| Q91615866 | Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study |
| Q37059101 | Chronic Peptide Therapy With B-Type Natriuretic Peptide in Patients With Pre-Clinical Diastolic Dysfunction (Stage B Heart Failure). |
| Q30359729 | Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure. |
| Q35611405 | Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population |
| Q92492724 | Circulating Neprilysin in Patients With Heart Failure and Preserved Ejection Fraction |
| Q55665074 | Circulating atrial natriuretic peptide genetic association study identifies a novel gene cluster associated with reduced NT-proANP, increased stroke and higher diastolic blood pressure. |
| Q35294797 | Circulating atrial natriuretic peptide genetic association study identifies a novel gene cluster associated with stroke in whites |
| Q50032150 | Clinical Significance of Early Fluid and Weight Change During Acute Heart Failure Hospitalization |
| Q37156991 | Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study |
| Q89051114 | Comparing Measures to Assess Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction |
| Q81262809 | Comparison of echocardiographic dyssynchrony assessment by tissue velocity and strain imaging in subjects with or without systolic dysfunction and with or without left bundle-branch block |
| Q37220814 | Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study |
| Q37366112 | Contractility and ventricular systolic stiffening in hypertensive heart disease insights into the pathogenesis of heart failure with preserved ejection fraction |
| Q51751552 | Coronary endothelial dysfunction and hyperlipidemia are independently associated with diastolic dysfunction in humans. |
| Q35072520 | Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction |
| Q37133494 | Death in heart failure: a community perspective |
| Q35071595 | Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure |
| Q51064876 | Defining high-sensitivity cardiac troponin concentrations in the community. |
| Q44877106 | Delayed intrinsicoid deflection onset in surface ECG lateral leads predicts left ventricular reverse remodeling after cardiac resynchronization therapy |
| Q36945854 | Depression, healthcare utilization, and death in heart failure: a community study |
| Q48772970 | Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction |
| Q38467462 | Diabetes in heart failure: prevalence and impact on outcome in the population |
| Q34989038 | Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension |
| Q36167458 | Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum |
| Q35998245 | Diastolic dysfunction and left atrial volume: a population-based study |
| Q43871204 | Diastolic heart failure in the community: clinical profile, natural history, therapy, and impact of proposed diagnostic criteria |
| Q37156981 | Diastolic relaxation and compliance reserve during dynamic exercise in heart failure with preserved ejection fraction |
| Q30530714 | Diastolic stiffness as assessed by diastolic wall strain is associated with adverse remodelling and poor outcomes in heart failure with preserved ejection fraction |
| Q36380451 | Dietary sodium modulation of aldosterone activation and renal function during the progression of experimental heart failure |
| Q38389015 | Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). |
| Q36141962 | Diuretic strategies in patients with acute decompensated heart failure |
| Q87691227 | Dopamine vs nesiritide for acute heart failure with renal dysfunction--reply |
| Q84582833 | Dyssynchrony indices to predict response to cardiac resynchronization therapy: a comprehensive prospective single-center study |
| Q36281427 | Echocardiographic characteristics of electrocardiographically unrecognized myocardial infarctions in a community population |
| Q58607822 | Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial |
| Q38376716 | Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial |
| Q98174749 | Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF |
| Q37328507 | Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial |
| Q38389314 | Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial |
| Q91314693 | Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF |
| Q35627898 | Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study |
| Q46710880 | Effects of omapatrilat on cardiac nerve sprouting and structural remodeling in experimental congestive heart failure |
| Q35630046 | Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction |
| Q44341438 | Effects of vasodilation in heart failure with preserved or reduced ejection fraction implications of distinct pathophysiologies on response to therapy |
| Q38374127 | Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial |
| Q28589777 | Elevated blood pressure and cardiac hypertrophy after ablation of the gly96/IEX-1 gene |
| Q47659132 | End-of-Life Discussions in Patients With Heart Failure |
| Q91998234 | Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction |
| Q36186620 | Epidemiology of diastolic heart failure |
| Q30234501 | Epidemiology of heart failure with preserved ejection fraction |
| Q39164596 | Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. |
| Q36564895 | Evaluation of a provocative dyspnea severity score in acute heart failure. |
| Q34623775 | Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction |
| Q38760688 | Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction |
| Q35950332 | Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection |
| Q44928023 | Exploratory study of relationship between hospitalized heart failure patients and chronic renal replacement therapy |
| Q38791497 | Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure: Current Status and Prospects for Further Research |
| Q40557635 | FOXO3a regulates BNIP3 and modulates mitochondrial calcium, dynamics, and function in cardiac stress |
| Q44355163 | Failing atrial myocardium: energetic deficits accompany structural remodeling and electrical instability |
| Q37202129 | Familial aggregation of left ventricular geometry and association with parental heart failure: the Framingham Heart Study |
| Q37095610 | Frailty and healthcare utilization among patients with heart failure in the community |
| Q37029837 | From statistical significance to clinical relevance: A simple algorithm to integrate brain natriuretic peptide and the Seattle Heart Failure Model for risk stratification in heart failure |
| Q33917887 | GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study |
| Q35206146 | Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). |
| Q24612121 | Genetic variants associated with cardiac structure and function: a meta-analysis and replication of genome-wide association data |
| Q34178646 | Global Cardiovascular Reserve Dysfunction in Heart Failure With Preserved Ejection Fraction |
| Q49791521 | Global Pulmonary Vascular Remodeling in Pulmonary Hypertension Associated with Heart Failure and Preserved or Reduced Ejection Fraction. |
| Q38294246 | Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish |
| Q91852181 | Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial |
| Q90718826 | Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials |
| Q56565864 | Heart Failure with Preserved Ejection Fraction |
| Q87716439 | Heart Failure with Preserved Ejection Fraction |
| Q89387122 | Heart Failure with Preserved Ejection Fraction |
| Q57540265 | Heart failure after myocardial infarction: clinical presentation and survival |
| Q36981702 | Heart failure performance measures: eligibility and implementation in the community |
| Q27024008 | Heart failure with preserved ejection fraction |
| Q78455644 | Heart failure--an epidemic of uncertain proportions |
| Q36499968 | Heart failure: a rose by any other name? |
| Q44167945 | Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension |
| Q38836623 | High-Output Heart Failure: A 15-Year Experience. |
| Q64971781 | High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. |
| Q58775176 | High-sensitivity C-reactive protein in heart failure with preserved ejection fraction |
| Q36407050 | High-sensitivity troponin I and amino-terminal pro--B-type natriuretic peptide predict heart failure and mortality in the general population |
| Q58611123 | History of Atrial Fibrillation and Trajectory of Decongestion in Acute Heart Failure |
| Q33577303 | Hospitalizations after heart failure diagnosis a community perspective |
| Q33698918 | Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. |
| Q38377133 | INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design |
| Q48235282 | Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide |
| Q81440059 | Impact of arterial load and loading sequence on left ventricular tissue velocities in humans |
| Q37678145 | Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study |
| Q37000861 | Impact of chronic changes in arterial compliance and resistance on left ventricular ageing in humans. |
| Q34324637 | Impact of general and central adiposity on ventricular-arterial aging in women and men. |
| Q36796620 | Impaired Right Ventricular-Pulmonary Arterial Coupling and Effect of Sildenafil in Heart Failure With Preserved Ejection Fraction: An Ancillary Analysis From the Phosphodiesterase-5 Inhibition to Improve Clinical Status And Exercise Capacity in Dias |
| Q36730711 | Impaired functional status and echocardiographic abnormalities signifying global dysfunction enhance the prognostic significance of previously unrecognized myocardial infarction detected by electrocardiography. |
| Q48310286 | Impaired left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: insights from the RELAX trial |
| Q30446941 | Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction |
| Q38388972 | Implications of Using Different Definitions on Outcomes in Worsening Heart Failure |
| Q34204378 | Incidence of heart failure after myocardial infarction: is it changing over time? |
| Q35207706 | Influence of sex and hormone status on circulating natriuretic peptides |
| Q38682105 | Inpatient Mortality Risk Scores and Postdischarge Events in Hospitalized Heart Failure Patients: A Community-Based Study |
| Q42679350 | Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial |
| Q92320033 | Interdependence of Atrial Fibrillation and Heart Failure With a Preserved Ejection Fraction Reflects a Common Underlying Atrial and Ventricular Myopathy |
| Q91501945 | Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in high-risk populations? Insights from the DAVID-Berg study |
| Q36459987 | Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction |
| Q36984053 | K(ATP) channel polymorphism is associated with left ventricular size in hypertensive individuals: a large-scale community-based study |
| Q39272526 | Left Atrial Remodeling and Atrioventricular Coupling in a Canine Model of Early Heart Failure With Preserved Ejection Fraction |
| Q36182164 | Left Atrial Structure and Function in Heart Failure with Preserved Ejection Fraction: A RELAX Substudy |
| Q86543015 | Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction |
| Q57540337 | Left atrial volume as an index ofleft atrial size: a population-based study |
| Q34414650 | Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction |
| Q48796657 | Left ventricular discoordination index measured by speckle tracking strain rate imaging predicts reverse remodelling and survival after cardiac resynchronization therapy |
| Q88724243 | Letter by Zakeri and Redfield Regarding Article, "Influence of Left Atrial Function on Exercise Capacity and Left Ventricular Function in Patients With Heart Failure and Preserved Ejection Fraction" |
| Q89544051 | Long-term blood pressure lowering and cGMP-activating actions of the novel ANP analog MANP |
| Q36866650 | Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction |
| Q37254231 | Longitudinal changes in left ventricular stiffness: a community-based study |
| Q37603555 | Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial |
| Q37397960 | Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure |
| Q36525043 | Membrane guanylyl cyclase receptors: an update |
| Q34121798 | Mineralocorticoid accelerates transition to heart failure with preserved ejection fraction via "nongenomic effects". |
| Q80627967 | Mineralocorticoid escape by the kidney but not the heart in experimental asymptomatic left ventricular dysfunction |
| Q46845277 | Mineralocorticoid signaling in transition to heart failure with normal ejection fraction |
| Q45930105 | Mitochondrial Integrity and Function in the Progression of Early Pressure Overload-Induced Left Ventricular Remodeling. |
| Q64375014 | Mitochondrial Morphology, Dynamics, and Function in Human Pressure Overload or Ischemic Heart Disease With Preserved or Reduced Ejection Fraction |
| Q43983240 | Mitral regurgitation in patients with advanced systolic heart failure |
| Q90698376 | Myocardial Energetics in Heart Failure With Preserved Ejection Fraction |
| Q35328760 | Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin |
| Q46445280 | Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure |
| Q34971920 | Natriuretic peptide pharmacogenetics: Membrane metallo-endopeptidase (MME): Common gene sequence variation, functional characterization and degradation |
| Q36936568 | Natriuretic peptide receptor-3 gene (NPR3): nonsynonymous polymorphism results in significant reduction in protein expression because of accelerated degradation |
| Q36770944 | Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications |
| Q33878162 | Nesiritide in acute decompensated heart failure: current status and future perspectives |
| Q35005829 | Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and design |
| Q53760213 | Nitrates in Heart Failure with Preserved Ejection Fraction. |
| Q48511734 | Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction |
| Q36564032 | Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide |
| Q36399698 | Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy |
| Q34756310 | Optimized delivery system achieves enhanced endomyocardial stem cell retention |
| Q96692559 | Outcomes of Incident Atrial Fibrillation in Heart Failure with Preserved or Reduced Ejection Fraction: A Community-Based Study |
| Q52966947 | Participation bias in a population-based echocardiography study. |
| Q39387575 | Patient Activation in Acute Decompensated Heart Failure |
| Q41927225 | PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design |
| Q92398977 | Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial) |
| Q37025044 | Physical health status measures predict all-cause mortality in patients with heart failure |
| Q34843144 | Plasma brain natriuretic peptide concentration: impact of age and gender |
| Q47377837 | Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study |
| Q92971792 | Predictive Value of the Get With The Guidelines Heart Failure Risk Score in Unselected Cardiac Intensive Care Unit Patients |
| Q35586340 | Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study |
| Q36758041 | Prevalence and prognostic significance of heart failure stages: application of the American College of Cardiology/American Heart Association heart failure staging criteria in the community |
| Q38788457 | Prevalence, Profile, and Prognosis of Severe Obesity in Contemporary Hospitalized Heart Failure Trial Populations. |
| Q37413803 | Prognostic value of biomarkers in heart failure: application of novel methods in the community |
| Q35719757 | Progression of left ventricular diastolic dysfunction and risk of heart failure |
| Q55489965 | Progressive decline in circulating CNP with aging is associated with progressive cardiac fibrosis and myocardial impairment. |
| Q42445262 | Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. |
| Q48223158 | Protein phosphatase 5 regulates titin phosphorylation and function at a sarcomere-associated mechanosensor complex in cardiomyocytes. |
| Q47882138 | Pulmonary Pressure Assessment with the Total Artificial Heart |
| Q40607302 | Pulmonary capillary wedge pressure augments right ventricular pulsatile loading. |
| Q37328944 | Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study |
| Q35673495 | Pulmonary pressures and death in heart failure: a community study |
| Q90158619 | Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity |
| Q97414701 | Racial Differences in Diuretic Efficiency, Plasma Renin, and Rehospitalization in Subjects With Acute Heart Failure |
| Q48315831 | Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction |
| Q38927295 | Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure |
| Q89918114 | Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserve |
| Q34989233 | Regulation of circulating progenitor cells in left ventricular dysfunction. |
| Q27340297 | Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute [...] |
| Q92600805 | Renal Dysfunction in Heart Failure With Preserved Ejection Fraction: Insights From the RELAX Trial |
| Q82414338 | Renal function and mortality following cardiac resynchronization therapy |
| Q90588213 | Research Priorities for Heart Failure With Preserved Ejection Fraction: National Heart, Lung, and Blood Institute Working Group Summary |
| Q43109461 | Response to Letter Regarding Article, “Effects of Sildenafil on Ventricular and Vascular Function in Heart Failure With Preserved Ejection Fraction”. |
| Q36299927 | Response to Letters Regarding Article, "Coronary Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection Fraction". |
| Q44592790 | Response to cardiac resynchronization therapy predicts survival in heart failure: a single-center experience |
| Q44285969 | Response to letter regarding article, "Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction". |
| Q54036928 | Response to letter regarding article, "right ventricular function in heart failure with preserved ejection fraction: a community-based study". |
| Q33992679 | Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study |
| Q33666358 | Resuscitation preferences in community patients with heart failure |
| Q80785074 | Revisiting methods for assessing and comparing left ventricular diastolic stiffness: impact of relaxation, external forces, hypertrophy, and comparators |
| Q35588220 | Right heart dysfunction in heart failure with preserved ejection fraction |
| Q34772384 | Right ventricular function in heart failure with preserved ejection fraction: a community-based study |
| Q83833425 | Right ventricular function in patients with preserved and reduced ejection fraction heart failure |
| Q38992994 | Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer |
| Q97528529 | Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial |
| Q57540203 | Secular Trends in Renal Dysfunction and Outcomes in Hospitalized Heart Failure Patients |
| Q35021981 | Self-rated health predicts healthcare utilization in heart failure |
| Q92691276 | Sex Differences in Exercise Capacity and Quality of Life in Heart Failure With Preserved Ejection Fraction: A Secondary Analysis of the RELAX and NEAT-HFpEF Trials |
| Q55029995 | Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial. |
| Q42149439 | Sildenafil and B-type natriuretic peptide acutely phosphorylate titin and improve diastolic distensibility in vivo |
| Q87203947 | Sildenafil and exercise capacity in heart failure--in reply |
| Q92179630 | Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease |
| Q37992316 | Strategies to screen for stage B as a heart failure prevention intervention |
| Q44853867 | Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure |
| Q38380593 | Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction. |
| Q82719583 | Symptom improvement after upgrade from right ventricular apical to biventricular pacing: Role of right and left ventricular volumes assessed with single-photon emission computed tomographic equilibrium radionuclide angiocardiography |
| Q48376632 | Systolic and diastolic heart failure in the community |
| Q42562973 | Target of rapamcyin (TOR)-based therapeutics for cardiomyopathy: insights from zebrafish genetics |
| Q37425473 | Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial |
| Q38646405 | Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection Fraction: Association With Baseline Disease Severity and Subsequent Outcome |
| Q37543186 | Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study |
| Q48532699 | The Breathing Not Proper trial: enough evidence to change heart failure guidelines? |
| Q34616035 | The effect of the brain-type natriuretic peptide single-nucleotide polymorphism rs198389 on test characteristics of common assays |
| Q36713575 | The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction |
| Q28543897 | The emperor's new clothes: PDE5 and the heart |
| Q35954254 | The natriuretic peptides in cardiovascular medicine |
| Q48532687 | The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure |
| Q33825297 | The prevalence of diabetic cardiomyopathy: a population-based study in Olmsted County, Minnesota |
| Q37163361 | The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects |
| Q35566135 | The role of brain natriuretic peptide in population screening |
| Q37426326 | Titin isoforms, extracellular matrix, and global chamber remodeling in experimental dilated cardiomyopathy: functional implications and mechanistic insight |
| Q81617451 | Treating diastolic heart failure with AGE crosslink breakers: thinking outside the heart failure box |
| Q57540294 | Trends in Heart Failure Incidence and Survival in a Community-Based Population |
| Q28252937 | Trends in prevalence and outcome of heart failure with preserved ejection fraction |
| Q47880853 | Triphasic mitral inflow velocity with middiastolic filling: clinical implications and associated echocardiographic findings. |
| Q37192858 | Tumor necrosis factor-alpha and mortality in heart failure: a community study |
| Q36949209 | Ultrafiltration in decompensated heart failure with cardiorenal syndrome |
| Q80055199 | Understanding "diastolic" heart failure |
| Q51770673 | Unexplained pulmonary hypertension in elderly patients. |
| Q48602051 | Unrecognized myocardial infarction: the association with cardiopulmonary symptoms and mortality is mediated via echocardiographic abnormalities of global dysfunction instead of regional dysfunction: the Olmsted County Heart Function Study |
| Q48292025 | Use of BNP and CRP as biomarkers in assessing cardiovascular disease: diagnosis versus risk |
| Q57540196 | Use of Ejection Fraction Tests and Coronary Angiography in Patients With Heart Failure |
| Q45085444 | Use of a novel ultrafiltration device as a treatment strategy for diuretic resistant, refractory heart failure: initial clinical experience in a single center |
| Q35102703 | Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure |
| Q36141950 | Variable phenotype in murine transverse aortic constriction |
| Q35651966 | Ventricular structure and function in aged dogs with renal hypertension: a model of experimental diastolic heart failure |
| Q37364471 | Ventricular-Arterial Function and Coupling in the Adult Fontan Circulation |
| Q37379777 | Who has advanced heart failure?: definition and epidemiology |
| Q37350630 | Zooming in on the Microvasculature in Heart Failure With Preserved Ejection Fraction |
Search more.